{
    "clinical_study": {
        "@rank": "35138", 
        "arm_group": {
            "arm_group_label": "Betanis", 
            "description": "the usual adult dosage of mirabegron once daily after a meal"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name:\n      mirabegron), and to determine the adherence to treatment with mirabegron."
        }, 
        "brief_title": "Long-Term Specified Drug Use-results Survey of Betanis Tablets", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who administer mirabegron for treatment of urinary urgency, daytime\n             frequency, and urgency incontinence associated with overactive bladder and also who\n             have no treatment history of mirabegron."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who administer mirabegron for treatment of urinary urgency, daytime frequency,\n        and urgency incontinence associated with overactive bladder and also who have no treatment\n        history of mirabegron."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901120", 
            "org_study_id": "BE0002"
        }, 
        "intervention": {
            "arm_group_label": "Betanis", 
            "description": "oral", 
            "intervention_name": "Betanis", 
            "intervention_type": "Drug", 
            "other_name": [
                "YM178", 
                "mirabegron"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "mirabegron", 
            "Betanis\u00ae", 
            "Overactive Bladder"
        ], 
        "lastchanged_date": "July 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tohoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Long-Term Specified Drug Use-results Survey of Betanis Tablets", 
        "overall_contact": {
            "email": "clinicaltrial.info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Central Contact", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Up to 36 months after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Overactive Bladder Symptom Score (OABSS)", 
            "safety_issue": "No", 
            "time_frame": "At the start of treatment and 3, 6, 12, 18, 24, 30, and 36 months after treatment"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}